Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Neurochem Int ; 53(3-4): 95-101, 2008 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-18598728

RESUMO

The accumulation of oxidatively modified proteins has been shown to be a characteristic feature of many neurodegenerative disorders and its regulation requires efficient proteolytic processing. One component of the mitochondrial proteolytic system is Lon, an ATP-dependent protease that has been shown to degrade oxidatively modified aconitase in vitro and may thus play a role in defending against the accumulation of oxidized matrix proteins in mitochondria. Using an assay system that allowed us to distinguish between basal and ATP-stimulated Lon protease activity, we have shown in isolated non-synaptic rat brain mitochondria that Lon protease is highly susceptible to oxidative inactivation by peroxynitrite (ONOO(-)). This susceptibility was more pronounced with regard to ATP-stimulated activity, which was inhibited by 75% in the presence of a bolus addition of 1mM ONOO(-), whereas basal unstimulated activity was inhibited by 45%. Treatment of mitochondria with a range of peroxynitrite concentrations (10-1000 microM) revealed that a decline in Lon protease activity preceded electron transport chain (ETC) dysfunction (complex I, II-III and IV) and that ATP-stimulated activity was approximately fivefold more sensitive than basal Lon protease activity. Furthermore, supplementation of mitochondrial matrix extracts with reduced glutathione, following ONOO(-) exposure, resulted in partial restoration of basal and ATP-stimulated activity, thus suggesting possible redox regulation of this enzyme complex. Taken together these findings suggest that Lon protease may be particularly vulnerable to inactivation in conditions associated with GSH depletion and elevated oxidative stress.


Assuntos
Encéfalo/enzimologia , Mitocôndrias/enzimologia , Doenças Mitocondriais/enzimologia , Estresse Oxidativo/fisiologia , Ácido Peroxinitroso/farmacologia , Protease La/metabolismo , Trifosfato de Adenosina/metabolismo , Trifosfato de Adenosina/farmacologia , Animais , Bioensaio , Encéfalo/fisiopatologia , Relação Dose-Resposta a Droga , Complexo de Proteínas da Cadeia de Transporte de Elétrons/efeitos dos fármacos , Complexo de Proteínas da Cadeia de Transporte de Elétrons/metabolismo , Metabolismo Energético/efeitos dos fármacos , Metabolismo Energético/fisiologia , Glutationa/farmacologia , Masculino , Mitocôndrias/efeitos dos fármacos , Doenças Mitocondriais/fisiopatologia , Estresse Oxidativo/efeitos dos fármacos , Protease La/antagonistas & inibidores , Ratos , Ratos Wistar , Fatores de Tempo
2.
Neurochem Res ; 32(4-5): 739-50, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17191138

RESUMO

Since the discovery of the significance of the cholesterol-carrying apolipoprotein E and cholesterolaemia as major risk factors for Alzheimer's Disease (AD) there has been a mounting interest in the role of this lipid as a possible pathogenic agent. In this review we analyse the current evidence linking cholesterol metabolism and regulation in the CNS with the known mechanisms underlying the development of Alzheimer's Disease. Cholesterol is known to affect amyloid-beta generation and toxicity, although it must be considered that the results studies using the statin class of drugs to lower plasma cholesterol may be affected by other effects associated with these drugs. Finally, we report some of our results pointing at the interplay between neurons and astrocytes and NADPH oxidase activation as a new candidate mechanism linking cholesterol and AD pathology.


Assuntos
Doença de Alzheimer/metabolismo , Colesterol/metabolismo , Doença de Alzheimer/tratamento farmacológico , Peptídeos beta-Amiloides/biossíntese , Peptídeos beta-Amiloides/toxicidade , Animais , Apolipoproteínas E/metabolismo , Sistema Nervoso Central/metabolismo , Humanos , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Metabolismo dos Lipídeos/fisiologia , Camundongos , NADPH Oxidases/metabolismo , Neuroglia/metabolismo , Doença de Niemann-Pick Tipo C/genética , Doença de Niemann-Pick Tipo C/metabolismo
3.
J Neurochem ; 95(2): 388-95, 2005 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16104850

RESUMO

Inhibition of the mitochondrial electron transport chain (ETC) ultimately limits ATP production and depletes cellular ATP. However, the individual complexes of the ETC in brain mitochondria need to be inhibited by approximately 50% before causing significant depression of ATP synthesis. Moreover, the ETC is the key site for the production of intracellular reactive oxygen species (ROS) and inhibition of one or more of the complexes of the ETC may increase the rate of mitochondrial ROS generation. We asked whether partial inhibition of the ETC, to a degree insufficient to perturb oxidative phosphorylation, might nonetheless induce ROS production. Chronic increase in mitochondrial ROS might then cause oxidative damage to the ETC sufficient to produce prolonged changes in ETC function and so compound the defect. We show that the exposure of astrocytes in culture to low concentrations of nitric oxide (NO) induces an increased rate of O2*- generation that outlasts the presence of NO. No effect was seen on oxygen consumption, lactate or ATP content over the 4-6 h that the cells were exposed to NO. These data suggest that partial ETC inhibition by NO may initially cause oxidative stress rather than ATP depletion, and this may subsequently induce irreversible changes in ETC function providing the basis for a cycle of damage.


Assuntos
Astrócitos/metabolismo , Metabolismo Energético/efeitos dos fármacos , Mitocôndrias/efeitos dos fármacos , Óxido Nítrico/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Trifosfato de Adenosina/metabolismo , Animais , Astrócitos/efeitos dos fármacos , Encéfalo/citologia , Química Encefálica/efeitos dos fármacos , Química Encefálica/fisiologia , Células Cultivadas , Cobre/metabolismo , Transporte de Elétrons/efeitos dos fármacos , Complexo IV da Cadeia de Transporte de Elétrons/metabolismo , Retroalimentação/fisiologia , Heme/metabolismo , Processamento de Imagem Assistida por Computador , Ácido Láctico/biossíntese , Microscopia Confocal , Mitocôndrias/enzimologia , NAD/metabolismo , Doadores de Óxido Nítrico/farmacologia , Consumo de Oxigênio/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley , Superóxidos/metabolismo
4.
J Neurochem ; 92(4): 840-9, 2005 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-15686486

RESUMO

Apoptosis may be initiated in neurons via mitochondrial release of the respiratory protein, cytochrome c. The mechanism of cytochrome c release has been studied extensively, but little is known about its dynamics. It has been claimed that release is all-or-none, however, this is not consistent with accumulating evidence of cytosolic mechanisms for 'buffering' cytochrome c. This study has attempted to model an underlying disease pathology, rather than inducing apoptosis directly. The model adopted was diminished activity of the mitochondrial respiratory chain complex I, a recognized feature of Parkinson's disease. Titration of rat brain mitochondrial respiratory function, with the specific complex I inhibitor rotenone, caused proportional release of cytochrome c from isolated synaptic and non-synaptic mitochondria. The mechanism of release was mediated, at least in part, by the mitochondrial outer membrane component Bak and voltage-dependent anion channel rather than non-specific membrane rupture. Furthermore, preliminary data were obtained demonstrating that in primary cortical neurons, titration with rotenone induced cytochrome c release that was subthreshold for the induction of apoptosis. Implications for the therapy of neurodegenerative diseases are discussed.


Assuntos
Apoptose/fisiologia , Encéfalo/enzimologia , Encéfalo/metabolismo , Citocromos c/metabolismo , Mitocôndrias/metabolismo , Doenças Neurodegenerativas/enzimologia , Animais , Apoptose/efeitos dos fármacos , Encéfalo/patologia , Células Cultivadas , Relação Dose-Resposta a Droga , Masculino , Potenciais da Membrana/efeitos dos fármacos , Potenciais da Membrana/fisiologia , Mitocôndrias/enzimologia , Mitocôndrias/patologia , Doenças Neurodegenerativas/patologia , Ratos , Ratos Wistar , Rotenona/farmacologia
5.
J Neurochem ; 87(2): 386-94, 2003 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-14511116

RESUMO

We have examined the action of nitric oxide (NO) on the ability of Fenton's reagent (ferrous iron and hydrogen peroxide), to oxidize a number of organic optical probes. We found that NO is able to arrest the oxidation of organic compounds at concentrations of NO found in brain, in vivo. We present evidence that Fenton's reagent proceeds via a ferryl intermediate ([Fe[double bond]O]2+), before the generation of hydroxyl radical *OH. NO reacts rapidly with this ferryl, blocking the production of *OH. We propose that NO has an important role in protecting biological tissues, and the brain in particular, from Fenton chemistry.


Assuntos
Antioxidantes/química , Peróxido de Hidrogênio/química , Ferro/química , Óxido Nítrico/química , Cobalto/química , Fluoresceína/química , Radical Hidroxila/química , Oxidantes/química , Oxirredução , Análise Espectral
6.
J Neurochem ; 83(4): 984-91, 2002 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-12421371

RESUMO

Cultured rat and human astrocytes and rat neurones were shown to release reduced glutathione (GSH). In addition, GSH oxidation was retarded by the concomitant release of a factor from the cells. One possibility is that this factor is extracellular superoxide dismutase (SOD). In support of this, the factor was found to bind heparin, have a molecular mass estimated to be between 50 and 100 kDa, and CuZn-type SOD protein and cyanide sensitive enzyme activity were demonstrated in the cell-conditioned medium. In addition, supplementation of native medium with exogenous CuZn-type SOD suppressed GSH oxidation. We propose that preservation of released GSH is essential to allow for maximal up-regulation of GSH metabolism in neurones. Furthermore, cytokine stimulation of astrocytes increased release of the extracellular SOD, and enhanced stability of GSH. This may be a protective strategy occurring in vivo under conditions of oxidative stress, and suggests that SOD mimetics may be of therapeutic use.


Assuntos
Astrócitos/metabolismo , Espaço Extracelular/metabolismo , Glutationa/metabolismo , Superóxido Dismutase/metabolismo , Animais , Astrócitos/citologia , Astrocitoma/metabolismo , Células Cultivadas , Cromatografia de Afinidade , Meios de Cultivo Condicionados/química , Meios de Cultivo Condicionados/metabolismo , Citocinas/farmacologia , Ensaio de Imunoadsorção Enzimática , Filtração , Heparina/metabolismo , Humanos , Peso Molecular , Neurônios/citologia , Neurônios/metabolismo , Oxirredução/efeitos dos fármacos , Ratos , Ratos Wistar , Superóxido Dismutase/farmacologia
7.
Biochem J ; 366(Pt 1): 97-107, 2002 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-11994046

RESUMO

Manganese-salen complexes (Mn-Salen), including EUK-8 [manganese N,N'-bis(salicylidene)ethylenediamine chloride] and EUK-134 [manganese 3-methoxy N,N'-bis(salicylidene)ethylenediamine chloride], have been reported to possess combined superoxide dismutase (SOD) and catalase mimetic functions. Because of this SOD/catalase mimicry, EUK-8 and EUK-134 have been investigated as possible therapeutic agents in neurological disorders resulting from oxidative stress, including Alzheimer's disease, Parkinson's disease, stroke and multiple sclerosis. These actions have been explained by the ability of the Mn-Salen to remove deleterious superoxide (O(2)(-)) and H(2)O(2). However, in addition to oxidative stress, cells in models for neurodegenerative diseases may also be subjected to damage from reactive nitrogen oxides (nitrosative stress), resulting from elevated levels of NO and sister compounds, including peroxynitrite (ONOO(-)). We have been examining the interaction of EUK-8 and EUK-134 with NO and ONOO(-). We find that in the presence of a per-species (H(2)O(2), ONOO(-), peracetate and persulphate), the Mn-Salen complexes are oxidized to the corresponding oxo-species (oxoMn-Salen). OxoMn-Salens are potent oxidants, and we demonstrate that they can rapidly oxidize NO to NO(2) and also oxidize nitrite (NO(2)(-) to nitrate (NO(2)(-)). Thus these Mn-Salens have the potential to ameliorate cellular damage caused by both oxidative and nitrosative stresses, by the catalytic breakdown of O(2)(-), H(2)O(2), ONOO(-) and NO to benign species: O(2), H(2)O, NO(2)(-) and NO(3)(-).


Assuntos
Catalase/metabolismo , Manganês/química , Óxido Nítrico/metabolismo , Oxigênio/metabolismo , Superóxido Dismutase/metabolismo , Animais , Astrócitos/metabolismo , Bovinos , Relação Dose-Resposta a Droga , Etilenodiaminas/química , Peróxido de Hidrogênio/metabolismo , Fígado/enzimologia , Compostos de Manganês/química , Modelos Químicos , Compostos Organometálicos/química , Estresse Oxidativo , Ratos , Ratos Wistar , Salicilatos/química , Sepse , Fatores de Tempo
8.
Anal Biochem ; 304(1): 26-32, 2002 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-11969185

RESUMO

The tripeptide glutathione (gamma-glutamylcysteinylglycine; GSH) is the predominant low molecular mass thiol in cells. The function of GSH is of considerable interest, with the molecule being implicated in numerous cellular processes in addition to being a major cellular antioxidant. The enzyme glutamate-cysteine ligase (GCL) is the rate-limiting step in GSH synthesis. The GCL assay described here is based on high-performance liquid chromatography and exploits the electrochemically active nature of gamma-glutamylcysteine (gamma-GC), the product of GCL activity. This method allows for the direct detection of gamma-GC rather than relying on derivatization of the molecule or linked assays. The sensitivity of the assay is sufficient to allow for the measurement of GCL activity in cultured cells. The specific activity of GCL in rat primary culture astrocytes was 9.7 +/- 1.7 nmol gamma-GC synthesized/min/mg protein.


Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Glutamato-Cisteína Ligase/análise , Animais , Astrócitos/enzimologia , Butionina Sulfoximina/farmacologia , Células Cultivadas , Cromatografia Líquida de Alta Pressão/normas , Dipeptídeos/análise , Eletroquímica , Inibidores Enzimáticos/farmacologia , Glutamato-Cisteína Ligase/antagonistas & inibidores , Glutamato-Cisteína Ligase/metabolismo , Glutationa/análise , Cinética , Ratos , Padrões de Referência
9.
Epilepsy Res ; 48(3): 157-68, 2002 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-11904234

RESUMO

Status epilepticus (SE) in humans and animal models results in significant cerebral damage and an increased risk of subsequent seizures, associated with a characteristic pattern of neuronal loss particularly affecting the hippocampus. Seizure related cell death is considered to be excitotoxic, but studies have been limited, concentrating on terminal events rather than initial mechanisms. We have studied the biochemical events in the first few days following SE. Self-sustaining limbic SE was induced in adult rats using perforant path stimulation, and animals were allowed to recover. Biochemical studies were performed at 16, 44 h and 8 days following SE, using spectrophotometric enzyme assays and HPLC on regional brain homogenates compared with those from sham-operated controls. Haematoxylin and eosin histology was also undertaken at each time point. Brain aconitase and alpha-ketoglutarate dehydrogenase (alphaKDH) activity were both significantly (P<0.05) reduced by approximately 20% in the first 16-44 h following status, but had returned to normal by 8 days. These enzymes are part of the tri-carboxylic acid (Krebbs) cycle in the mitochondrial matrix, and are known to be sensitive to free radical, especially peroxynitrite damage. There was a similar decrease in reduced glutathione levels. Histological studies confirmed evidence of acute neuronal damage up to 44 h, and neuronal loss by 8 days. This is the first in vivo demonstration of this pattern of mitochondrial dysfunction and loss of brain glutathione following SE. The pattern of abnormalities is consistent with reversible mechanisms being involved in excitotoxic cell damage. This, together with the timing of changes, suggests new avenues for therapeutic intervention.


Assuntos
Mitocôndrias/metabolismo , Mitocôndrias/patologia , Neurônios/metabolismo , Neurônios/patologia , Estado Epiléptico/metabolismo , Estado Epiléptico/patologia , Animais , Morte Celular/fisiologia , Glutationa/metabolismo , Hipocampo/metabolismo , Hipocampo/patologia , Masculino , Ratos , Ratos Sprague-Dawley
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...